Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Temporal and sex differences in the role of BDNF/TrkB signaling in hyperalgesic priming in mice and rats.

Moy JK, Szabo-Pardi T, Tillu DV, Megat S, Pradhan G, Kume M, Asiedu MN, Burton MD, Dussor G, Price TJ.

Neurobiol Pain. 2018 Oct 19;5:100024. doi: 10.1016/j.ynpai.2018.10.001. eCollection 2019 Jan-Jul.

2.

Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming in mice.

Burton MD, Tillu DV, Mazhar K, Mejia GL, Asiedu MN, Inyang K, Hughes T, Lian B, Dussor G, Price TJ.

Neuroscience. 2017 Sep 17;359:119-129. doi: 10.1016/j.neuroscience.2017.07.020. Epub 2017 Jul 17.

3.

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.

Hanamura K, Washburn HR, Sheffler-Collins SI, Xia NL, Henderson N, Tillu DV, Hassler S, Spellman DS, Zhang G, Neubert TA, Price TJ, Dalva MB.

PLoS Biol. 2017 Jul 18;15(7):e2002457. doi: 10.1371/journal.pbio.2002457. eCollection 2017 Jul.

4.

The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo.

Boitano S, Hoffman J, Flynn AN, Asiedu MN, Tillu DV, Zhang Z, Sherwood CL, Rivas CM, DeFea KA, Vagner J, Price TJ.

Br J Pharmacol. 2015 Sep;172(18):4535-4545. doi: 10.1111/bph.13238. Epub 2015 Aug 3.

5.

Spinal dopaminergic projections control the transition to pathological pain plasticity via a D1/D5-mediated mechanism.

Kim JY, Tillu DV, Quinn TL, Mejia GL, Shy A, Asiedu MN, Murad E, Schumann AP, Totsch SK, Sorge RE, Mantyh PW, Dussor G, Price TJ.

J Neurosci. 2015 Apr 22;35(16):6307-17. doi: 10.1523/JNEUROSCI.3481-14.2015.

6.

Protease-activated receptor 2 activation is sufficient to induce the transition to a chronic pain state.

Tillu DV, Hassler SN, Burgos-Vega CC, Quinn TL, Sorge RE, Dussor G, Boitano S, Vagner J, Price TJ.

Pain. 2015 May;156(5):859-67. doi: 10.1097/j.pain.0000000000000125.

7.

Local translation and retrograde axonal transport of CREB regulates IL-6-induced nociceptive plasticity.

Melemedjian OK, Tillu DV, Moy JK, Asiedu MN, Mandell EK, Ghosh S, Dussor G, Price TJ.

Mol Pain. 2014 Jul 4;10:45. doi: 10.1186/1744-8069-10-45.

8.

Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering.

Boitano S, Hoffman J, Tillu DV, Asiedu MN, Zhang Z, Sherwood CL, Wang Y, Dong X, Price TJ, Vagner J.

PLoS One. 2014 Jun 13;9(6):e99140. doi: 10.1371/journal.pone.0099140. eCollection 2014.

9.

BDNF regulates atypical PKC at spinal synapses to initiate and maintain a centralized chronic pain state.

Melemedjian OK, Tillu DV, Asiedu MN, Mandell EK, Moy JK, Blute VM, Taylor CJ, Ghosh S, Price TJ.

Mol Pain. 2013 Mar 20;9:12. doi: 10.1186/1744-8069-9-12.

10.

Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.

Flynn AN, Hoffman J, Tillu DV, Sherwood CL, Zhang Z, Patek R, Asiedu MN, Vagner J, Price TJ, Boitano S.

FASEB J. 2013 Apr;27(4):1498-510. doi: 10.1096/fj.12-217323. Epub 2013 Jan 4.

11.

Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.

Hoffman J, Flynn AN, Tillu DV, Zhang Z, Patek R, Price TJ, Vagner J, Boitano S.

Bioconjug Chem. 2012 Oct 17;23(10):2098-104. doi: 10.1021/bc300300q. Epub 2012 Oct 8.

12.

Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain.

Tillu DV, Melemedjian OK, Asiedu MN, Qu N, De Felice M, Dussor G, Price TJ.

Mol Pain. 2012 Jan 23;8:5. doi: 10.1186/1744-8069-8-5.

13.

Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain.

Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, Khoutorsky A, Johnson J, Peebles KA, Lepow T, Sonenberg N, Dussor G, Price TJ.

Mol Pain. 2011 Sep 21;7:70. doi: 10.1186/1744-8069-7-70.

14.

Spinal protein kinase M ΞΆ underlies the maintenance mechanism of persistent nociceptive sensitization.

Asiedu MN, Tillu DV, Melemedjian OK, Shy A, Sanoja R, Bodell B, Ghosh S, Porreca F, Price TJ.

J Neurosci. 2011 May 4;31(18):6646-53. doi: 10.1523/JNEUROSCI.6286-10.2011.

15.

The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.

Flynn AN, Tillu DV, Asiedu MN, Hoffman J, Vagner J, Price TJ, Boitano S.

J Biol Chem. 2011 May 27;286(21):19076-88. doi: 10.1074/jbc.M110.185264. Epub 2011 Apr 5.

16.

IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex.

Melemedjian OK, Asiedu MN, Tillu DV, Peebles KA, Yan J, Ertz N, Dussor GO, Price TJ.

J Neurosci. 2010 Nov 10;30(45):15113-23. doi: 10.1523/JNEUROSCI.3947-10.2010.

17.

Supplemental Content

Loading ...
Support Center